JAAHA Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chun, R.
Right arrow Articles by Azene, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chun, R.
Right arrow Articles by Azene, N. M.
Journal of the American Animal Hospital Association 41:382-387 (2005)
© 2005 American Animal Hospital Association

Retrospective Study

Toxicity and Efficacy of Cisplatin and Doxorubicin Combination Chemotherapy for the Treatment of Canine Osteosarcoma

Ruthanne Chun, DVM, Diplomate ACVIM (Oncology), Laura D. Garrett, DVM, Diplomate ACVIM (Oncology), Carolyn Henry, DVM, MS, Diplomate ACVIM (Oncology), Michelle Wall, DVM, Diplomate ACVIM (Small Animal Internal, Medicine), Annette Smith, DVM, MS, Diplomate ACVIM (Small Animal Internal Medicine, Oncology) and Nicole M. Azene, MS

From the Department of Clinical Sciences (Chun, Garrett), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506; Department of Medicine and Surgery (Henry, Azene), College of Veterinary Medicine, University of Missouri, Columbia, Missouri 65211; Department of Small Animal Medicine and Surgery (Wall), College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602; and the Department of Clinical Sciences (Smith), College of Veterinary Medicine, Auburn University, Auburn, Alabama 36849.

Thirty-five dogs with appendicular osteosarcoma underwent amputation and chemotherapy with cisplatin and doxorubicin every 21 days for up to four cycles. Sixteen dogs completed all four cycles. Two dogs had therapy discontinued because of metastases. The remaining 17 dogs experienced toxicities necessitating protocol alteration or discontinuation. The median survival time of 300 days was not improved over previously reported single-agent protocols, but the 10 dogs that survived to a year lived a median of 510 days.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Animal Hospital Association.